About scPharmaceuticals
scPharmaceuticals is a publicly listed company based in Lexington (United States) founded in 2013, and was acquired by MannKind Corp in August 2025. scPharmaceuticals has raised $78.75 million across 4 funding rounds from investors including MannKind Corp, Sun Pharma and Orbimed. The company has 164 employees. scPharmaceuticals offers products and services including FUROSCIX. Its focus areas include Life Sciences, Drug Delivery and Patches. Its legal entity is scPharmaceuticals Inc. Its competitors include Valeritas, Incline Therapeutics and VeraDermics; 3 of its 3 listed competitors have raised funding.
Company details
Provider of a device for subcutaneous drug delivery for the treatment of bacterial infections and heart failure. The company has developed a device called sc2Wear Pump that facilitates subcutaneous drug administration over durations, rates, and volumes that can be tailored to specific drugs. The pipeline includes Furosemide for heart failure, Ceftriaxone, and Ertapenem to treat bacterial infections.
- Headquarters Lexington, United States
- Employees 164
- Stage Public
- SectorsHealthcare
- Website category Health · Biotechnology and Pharmaceuticals
- Website scpharmaceuticals.com
- Social LinkedIn X Facebook
- Acquired by MannKind Corp (Aug 2025)
- Legal Name Scpharmaceuticals Inc.
- Annual Revenue$36.33 M (USD)167.28as on Dec 31, 2024
- Net Profit-$85.15 M (USD)-55.35as on Dec 31, 2024
- EBITDA-$64.63 M (USD)-18as on Dec 31, 2024
- Total Equity Funding$78.75M (USD)
in 4 rounds
- Latest Funding Round$46.96M (USD), Series B
Jan 2017
- InvestorsMannKind Corp
& 5 more
- Employee Count164
- Acquired byMannKind Corp
(Aug 2025)
Products & Services of scPharmaceuticals
scPharmaceuticals offers a comprehensive portfolio of products and services, including FUROSCIX.
Treats heart failure and kidney disease via subcutaneous delivery.
Funding Insights of scPharmaceuticals
scPharmaceuticals has successfully raised a total of $78.75M across 4 strategic funding rounds. The most recent funding activity was a Series B round of $46.96 million completed in January 2017. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $78.75M
- Total Rounds 4
- Last Round Series B — $46.96M
- First Round $16M
(Mar 2014)
- Investors Count 5
All 4 funding rounds of scPharmaceuticals with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jan 2017 | $46.96M | Series B | – | Orbimed, Sun Pharma | |
| Sep 2016 | $12.18M | Series A | – | – | – |
| Feb 2016 | $3.6M | Series A | – | – | – |
| Mar 2014 | $16M | Series A | – | – |
6 investors in total: 6 institutional.
Investors in scPharmaceuticals
scPharmaceuticals has secured backing from 6 investors, including venture fund and institutional investors. Prominent investors backing the company include MannKind Corp, Sun Pharma and Orbimed.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Investments are made by OrbiMed in global healthcare innovations across biopharmaceuticals and related fields. | 1989 | orbimed.com | New York, United States | |
Venture capital fund backed incubator focused on the healthcare startups | 5amventures.com | San Francisco, United States | ||
Life science companies are funded through venture capital investments. | lundbeckfonden.com | Copenhagen, Denmark | ||
Private equity and venture captial firm focused on healthcare sectors | gildehealthcare.com | Cambridge, United States | ||
Specialty generic pharmaceuticals and APIs are manufactured and marketed. | 1983 | sunpharma.com | Mumbai, India | |
Developer of small-molecule drugs | 1991 | mannkindcorp.com | Los Angeles, United States |
Investor details for scPharmaceuticals
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
IPO & Listings of scPharmaceuticals
scPharmaceuticals is a publicly listed company on the NASDAQ with ticker symbol SCPH in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date17 Nov 2017
- Listed onNASDAQ: SCPH
- Listed entityscPharmaceuticals Inc.
- Exchange sectorHealth technology
- Share price$5.65 (+0.71% on the day) · 2025-09-29
- Market capitalisation$303.3M
- EPS (diluted, trailing year)$-1.81
- Volume (last session)2,762,224
- Analyst consensusNeutral
Financials of scPharmaceuticals
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2024 | $36.3M | -$85.2M | -$64.6M |
| 2023 | $13.6M | -$54.8M | -$54.8M |
| 2022 | -$36.8M | -$35.7M | |
| 2021 | -$28.0M | -$25.4M | |
| 2020 | -$32.2M | -$29.5M |
Detailed financial statements for scPharmaceuticals
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Timeline of scPharmaceuticals
5 dated milestones of scPharmaceuticals across 12 years, from founding to its latest funding, stage changes and deals.
- Founded scPharmaceuticals is founded.
- Funding First funding round of $16.0M.
- Funding Latest funding round, Series B, of $47.0M.
- IPO Lists on the stock exchange (IPO).
- Exit Acquired by MannKind Corp.
Competitors of scPharmaceuticals
scPharmaceuticals has 3 listed competitors in our database, 3 of them funded. They include Valeritas, Incline Therapeutics and VeraDermics.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| valeritas.com | 2003 | Bridgewater, United States | $181.36M | 141 | Wearable insulin patch pumps are developed for transdermal delivery. | |
| inclinethera.com | 2009 | Redwood, United States | $43.94M | Hospital-focused specialty pharmaceuticals are developed for acute pain management. | ||
| veradermics.com | 2020 | San Antonio, United States | $262.71M | Drug-delivery platforms for pediatric wart treatments are developed. |
Detailed competitors of scPharmaceuticals
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of scPharmaceuticals
- Unique visitors1K
per month
- Global rank#6,767,092
among all websites
- Category rank#6,759
Health · Biotechnology and Pharmaceuticals
- Bounce rate40%
- Pages per visit1.7
- Average visit18 sec
- DevicesDesktop 32% · Mobile 68%
Top companies in Biopharma Outsourcing & Drug Delivery
3 companies that operate in the same segment as scPharmaceuticals (Biopharma Outsourcing & Drug Delivery) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Suite solutions are provided for payers and healthcare providers. | 1998 | Princeton, New Jersey, United States | USD 220 M | USD 374.1 M | 4,490 | |
Wearable insulin infusion systems are developed for diabetes patients. | 2000 | Boston, Massachusetts, United States | USD 120.4 M | USD 2.71 B | 3,900 | |
Developer of small-molecule drugs | 1991 | Los Angeles, California, United States | USD 50 M | USD 348.97 M | 407 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Scpharmaceuticals
Complete news archive for scPharmaceuticals
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about scPharmaceuticals
scPharmaceuticals was founded in 2013 and raised its 1st funding round 1 year after it was founded.
scPharmaceuticals is headquartered in Lexington, United States. It is registered at Lexington, Kentucky, United States.
scPharmaceuticals is a funded company, having raised a total of $78.75M across 4 funding rounds to date. The company's 1st funding round was a Series A of $16M, raised on Mar 2014.
scPharmaceuticals has 164 employees.
Annual revenue of scPharmaceuticals is $36.33M as on Dec 31, 2024.
Provider of a device for subcutaneous drug delivery for the treatment of bacterial infections and heart failure. The company has developed a device called sc2Wear Pump that facilitates subcutaneous drug administration over durations, rates, and volumes that can be tailored to specific drugs. The pipeline includes Furosemide for heart failure, Ceftriaxone, and Ertapenem to treat bacterial infections.
scPharmaceuticals's top competitors include VeraDermics, Valeritas and Incline Therapeutics.
scPharmaceuticals offers FUROSCIX.
Yes, scPharmaceuticals is publicly traded on NASDAQ under the ticker symbol SCPH.
scPharmaceuticals has 6 investors. Key investors include MannKind Corp, Sun Pharma, Orbimed, 5AM Ventures, and Lundbeck Foundation.
scPharmaceuticals operates through Scpharmaceuticals Inc.
Yes. scPharmaceuticals was acquired by MannKind Corp in August 2025.